AnaptysBio, Inc. has initiated an antibody development program with Momenta Pharmaceuticals focused on the development of novel antibodies against an undisclosed target. AnaptysBio will receive an upfront fee in exchange for an option to acquire antibodies generated using its SHM-XEL platform against a specific therapeutic target. Financial terms were not disclosed.
"AnaptysBio's platform technology and antibody development capabilities have been strongly validated by numerous successful partnerships," said Hamza Suria, AnaptysBio's president and chief executive officer. "We look forward to working with Momenta on the development of these exciting new antibodies for unmet medical needs."